SecBot

SecBot
NYSE· Pharmaceutical Preparations· Inc. K7· CIK 0001135951

RDY

DR REDDYS LABORATORIES LTD
$12.26 ▲ +0.08%
Prev close $12.25
Market cap$10.5B
ConsensusSell
12-mo target$13.29 (+8.4%)
▼ Bearish
Analyst conviction 3/10
18 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RDY right now — valuation, ownership and activity at a glance.
Market Cap
$10.5B
Cap Size
Large Cap
Analyst Consensus
Hold (31%)
Inst. Holders
50 funds
Inst. Value
$1.5B
Inst. Activity
18 buys / 14 sells
SEC Reports
20
Price chart 30d +0.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
Sep 14, 2026 SEC
Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepe
6-K — Impact 3/10
Sep 10, 2026 SEC
No summary provided
6-K — Impact 5/10
Sep 10, 2026 SEC
Dr. Reddy's filed a routine 6-K reporting the allotment of 375 equity shares upon exercise of stock options under its AD
6-K — Impact 2/10
Jun 30, 2026 Inst.
ALLIANCEBERNSTEIN L.P. — ADD
3,730,713 shares ($51.7M)
Jun 30, 2026 Inst.
Nuveen, LLC — NEW
2,827,699 shares ($41.0M)
Jun 1, 2026 Event
Valganciclovir
WARNING: HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENES
Analyst ratings buy % +6.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Sell 31% rate it Buy or better · 45 analysts
Strong Buy 5 11% Buy 9 20% Hold 11 24% Sell 14 31% Strong Sell 6 13%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 29, 2026CitigroupUPGRADEBuy 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 2026591114631%
Aug 1, 2026591213631%
Jul 1, 2026815107452%
Jun 1, 2026815107452%
May 1, 2026814108450%
Apr 1, 2026914117451%
Mar 1, 2026913117450%
Feb 1, 2026913117450%
Price targets
Where 5 covering analysts think RDY trades over the next 12 months.
$13.29 +8.4% upside Buy
Current$12.26 Low$11.29 Median$12.98 High$15.30 5 analysts
$11.29$15.30
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 1 bullish, 3 bearish, 1 mixed, 15 neutral · avg impact 3.3/10.
NEUTRAL6-K3/10
Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facilit
Sep 14, 2026
NEUTRAL6-K5/10
No summary provided
Sep 10, 2026
NEUTRAL6-K2/10
Dr. Reddy's filed a routine 6-K reporting the allotment of 375 equity shares upon exercise of stock
Sep 10, 2026
NEUTRAL6-K2/10
Dr. Reddy's filed a routine 6-K on August 26, 2026, disclosing the allotment of 4,110 equity shares
Aug 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy'
Sep 21, 2026
short_volume
Short Volume: RDY — 59.5% short (0.5M / 0.9M)
Short: 537,265 | Exempt: 13 | TRF Vol: 902,419 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_interest_report
Short Interest: RDY up 21% to 29.0M shares
Settlement 2026-09-15 | Days to cover: 9.01 | ≈3.47% of shares outstanding (est.)
Sep 14, 2026
ftd
FTD: RDY — 302,977 shares ($3.6M) failed to deliver
Settlement: 20260914, Price: $11.90, FTD Value: $3,605,426.3, DR. REDDY'S LABORATORIES ADS
Sep 11, 2026
ftd
FTD: RDY — 80,594 shares ($0.9M) failed to deliver
Settlement: 20260911, Price: $11.71, FTD Value: $943,755.74, DR. REDDY'S LABORATORIES ADS
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.00$0.00–$0.00———$84.5B—
Next Q$0.00$0.00–$0.00———$89.9B—
Current FY$43.85$43.85–$43.85-20.8%-14.1%0↑ 1↓$352.0B1
Next FY$62.08$62.08–$62.0841.6%-2.0%0↑ 1↓$392.8B1
Institutional ownership
Which big funds own RDY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.5B total value (106,734,926 shares) as of 2026-Q2. Top holders: Erste, Robeco, MORGAN. Net buying activity: 18 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
Erste Asset Management GmbH0$0.000.0%—
Robeco Institutional Asset Management B.V.18,021,100$261.1M16.9%ADD +30.6%
MORGAN STANLEY10,936,320$158.5M10.2%—
BlackRock, Inc.10,585,742$153.4M9.9%—
ROYAL BANK OF CANADA9,213,269$133.5M8.6%—
RENAISSANCE TECHNOLOGIES LLC7,347,028$106.5M6.9%—
DIMENSIONAL FUND ADVISORS LP5,312,065$77.0M5.0%—
JPMORGAN CHASE & CO4,069,357$60.5M3.9%—
STATE STREET CORP4,124,686$59.8M3.9%—
ALLIANCEBERNSTEIN L.P.3,730,713$51.7M3.3%ADD +46.8%
Recent position changes
FundActionPrevCurrentChangeValue
ALLIANCEBERNSTEIN L.P.ADD2,541,8893,730,713+46.8%$51.7M
Nuveen, LLCNEW—2,827,699—$41.0M
SCHRODER INVESTMENT MANAGEMENT GROUPDOUBLED181,2391,618,404+793.0%$24.0M
GOLDMAN SACHS GROUP INCADD602,8361,053,487+74.8%$15.3M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED102,643489,102+376.5%$7.1M
MILLENNIUM MANAGEMENT LLCDOUBLED57,035468,375+721.2%$6.8M
Man Group plcDOUBLED73,752371,768+404.1%$5.4M
Connor, Clark & Lunn Investment Management Ltd.TRIM382,976231,979-39.4%$3.4M
US BANCORP \DE\ADD146,928189,028+28.7%$2.7M
Fisher Asset Management, LLCTRIM364,745180,767-50.4%$2.6M
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RDY.
Shares short
28,958,755
Settlement Sep 15, 2026
Change vs prior
+21.2%
Semi-monthly cycle
Days to cover
9.0
At avg daily volume
Of shares outstanding
≈3.5%
Estimate — not % of float
All RDY filing & press-release reports (51)